The frequency of both CD19+CD24hiCD38hi cells (Fig. 1a, b) and CD19+PD-L1hi cells (Fig. 2a, b) was significantly reduced in MS-relapse compared to MS-remission and HC. This evidence concerns the gene CD19 and myeloid sarcoma.